Aneurismal subarachnoid hemorrhage during the COVID-19 outbreak in a Hub and Spoke system: observational multicenter cohort study in Lombardy, Italy - Summary - MDSpire

Aneurismal subarachnoid hemorrhage during the COVID-19 outbreak in a Hub and Spoke system: observational multicenter cohort study in Lombardy, Italy

  • By

  • Alessandro Fiorindi

  • Marika Vezzoli

  • Francesco Doglietto

  • Luca Zanin

  • Giorgio Saraceno

  • Edoardo Agosti

  • Antonio Barbieri

  • Silvio Bellocchi

  • Claudio Bernucci

  • Daniele Bongetta

  • Andrea Cardia

  • Emanuele Costi

  • Marcello Egidi

  • Antonio Fioravanti

  • Roberto Gasparotti

  • Carlo Giussani

  • Gianluca Grimod

  • Nicola Latronico

  • Davide Locatelli

  • Dikran Mardighian

  • Giovanni Nodari

  • Jacopo Carlo Poli

  • Frank Rasulo

  • Elena Roca

  • Giovanni Marco Sicuri

  • Giannantonio Spena

  • Roberto Stefini

  • Oscar Vivaldi

  • Cesare Zoia

  • Stefano Calza

  • Marco Maria Fontanella

  • Marco Cenzato

  • October 25, 2021

  • 0 min

Share

Objective:

To evaluate the impact of the COVID-19 pandemic on the management and outcomes of aneurismal subarachnoid hemorrhage (aSAH) in Lombardy, Italy, focusing on diagnostic and therapeutic delays.

Key Findings:
  • 72 patients with aSAH during COVID-19 vs. 179 pre-pandemic, indicating a potential decrease in cases.
  • Significant increase in diagnostic delay during COVID-19 (+68%), highlighting the urgency of addressing this issue.
  • No significant differences in Fisher and WFNS grades between groups, suggesting clinical severity remained stable.
  • Only 5.5% of patients tested positive for SARS-CoV-2, indicating a low prevalence in this cohort.
Interpretation:

The COVID-19 pandemic led to increased diagnostic delays for aSAH, which may have critical implications for patient outcomes, but did not significantly alter clinical severity or treatment types compared to pre-pandemic periods.

Limitations:
  • Retrospective data collection may introduce bias, potentially affecting the reliability of findings.
  • Limited number of patients in the COVID-19 group may restrict the generalizability of results.
Conclusion:

The study highlights the challenges in managing aSAH during the COVID-19 pandemic, particularly regarding diagnostic delays, while treatment outcomes remained comparable to pre-pandemic levels, underscoring the need for improved strategies in future crises.

Original Source(s)

Related Content